

2009

Initiation of invasive disease in M1T1 group A streptococcus

Andrew Hollands
University of Wollongong

Follow this and additional works at: <https://ro.uow.edu.au/theses>

University of Wollongong

Copyright Warning

You may print or download ONE copy of this document for the purpose of your own research or study. The University does not authorise you to copy, communicate or otherwise make available electronically to any other person any copyright material contained on this site.

You are reminded of the following: This work is copyright. Apart from any use permitted under the Copyright Act 1968, no part of this work may be reproduced by any process, nor may any other exclusive right be exercised, without the permission of the author. Copyright owners are entitled to take legal action against persons who infringe their copyright. A reproduction of material that is protected by copyright may be a copyright infringement. A court may impose penalties and award damages in relation to offences and infringements relating to copyright material.

Higher penalties may apply, and higher damages may be awarded, for offences and infringements involving the conversion of material into digital or electronic form.

Unless otherwise indicated, the views expressed in this thesis are those of the author and do not necessarily represent the views of the University of Wollongong.

Recommended Citation

Hollands, Andrew, Initiation of invasive disease in M1T1 group A streptococcus, Doctor of Philosophy thesis, School of Biological Sciences, Faculty of Science, University of Wollongong, 2009.
<https://ro.uow.edu.au/theses/3070>

NOTE

This online version of the thesis may have different page formatting and pagination from the paper copy held in the University of Wollongong Library.

UNIVERSITY OF WOLLONGONG

COPYRIGHT WARNING

You may print or download ONE copy of this document for the purpose of your own research or study. The University does not authorise you to copy, communicate or otherwise make available electronically to any other person any copyright material contained on this site. You are reminded of the following:

Copyright owners are entitled to take legal action against persons who infringe their copyright. A reproduction of material that is protected by copyright may be a copyright infringement. A court may impose penalties and award damages in relation to offences and infringements relating to copyright material. Higher penalties may apply, and higher damages may be awarded, for offences and infringements involving the conversion of material into digital or electronic form.

Initiation of Invasive Disease in M1T1 Group A Streptococcus

A Thesis Submitted in Fulfilment of the Requirements

For the Award of the Degree

Doctor of Philosophy (PhD)

From the

University of Wollongong

By

Andrew Hollands

School of Biological Sciences

2009

DECLARATION

I, Andrew Hollands, declare that this thesis, submitted in fulfilment of the requirements for the award of Doctor of Philosophy (PhD), in the School of Biological Sciences, University of Wollongong, is wholly my own work unless otherwise referenced or acknowledged. The document has not been submitted for qualifications at any other academic institution.

A handwritten signature in black ink, appearing to read 'A Hollands', with a stylized, cursive script.

Andrew Hollands

30 November, 2009

ABSTRACT

Streptococcus pyogenes (group A streptococcus; GAS) is an important human pathogen that colonizes epithelial and mucosal surfaces. Group A streptococcal disease can be relatively minor, such as streptococcal pharyngitis, or severe and life-threatening, such as necrotizing fasciitis. There has been a resurgence of severe infection with GAS since the mid-1980s that has been paralleled by the emergence of a globally disseminated clone, M1T1. The M1T1 clone of GAS presents as the most common cause of streptococcal pharyngitis in developed countries and are also overrepresented in cases of severe infection.

Most invasive bacterial infections are caused by species that more commonly colonize the human host with minimal or no symptoms. Although phenotypic or genetic correlates underlying a bacterium's shift to enhanced virulence potential have been studied, the *in vivo* selection pressures governing such shifts are poorly understood. The globally disseminated M1T1 clone of GAS is linked with the rare but life-threatening syndromes of necrotizing fasciitis and toxic shock syndrome. Mutations in the group A streptococcal control of virulence regulatory sensor kinase (*covR/S*) operon are associated with severe invasive disease, abolishing expression of a broad spectrum cysteine protease (SpeB) and allowing the recruitment and activation of host plasminogen on the bacterial surface. This study describes how a bacteriophage-encoded group A streptococcal DNase (Sda1), which facilitates the pathogen's escape from neutrophil extracellular traps (NETs), can serve as a selective force for *covR/S* mutation. The results provide a paradigm whereby horizontal gene transfer and natural selection exerted by the innate immune system

generate hypervirulent bacterial variants with increased risk of systemic dissemination.

This study sought to investigate if there was a cost of fitness associated with *covR/S* mutation that counterbalances the dramatic increase in virulence. It was found that *covR/S* mutant bacteria had reduced capacity to bind fibronectin and collagen, both components of the extracellular matrix bound by streptococcal adhesins. The *covR/S* mutant strain examined in this study also showed reduced capacity to bind to epithelial cell layers as a consequence of increased capsule expression. This mutant strain displayed reduced capacity to form biofilms. An animal model of skin colonization was used to show that the *covR/S* mutant strain has a colonization defect. This reduced capacity to colonize presents an explanation as to why hypervirulent *covR/S* mutant M1T1 group A streptococci are not rapidly spread amongst the community.

The role of SpeB in the course of infection is still unclear. This study utilized a SpeB-negative M1T1 clinical isolate, 5628, with a naturally occurring mutation in the gene encoding the regulator RopB, to elucidate the role of RopB and SpeB in systemic virulence. Allelic exchange mutagenesis was used to replace the mutated *ropB* allele in 5628 with the intact allele from the well characterized isolate 5448. The inverse allelic exchange was also performed to replace the intact *ropB* in 5448 with the mutated allele from 5628. An intact *ropB* was found to be essential for SpeB expression. While the *ropB* mutation was shown to have no effect on haemolysis of RBCs, extracellular DNase activity or survival in the presence of neutrophils, strains with the mutated *ropB* allele were less virulent in murine systemic models of

infection. An isogenic SpeB knockout strain containing an intact RopB showed similarly reduced virulence. Microarray analysis found genes of the SpeB operon to be the primary target of RopB regulation. These data show that an intact RopB and efficient SpeB production are necessary for systemic infection with GAS.

ACKNOWLEDGEMENTS

First and foremost I would like to thank my supervisors, Prof. Mark Walker, and Prof. Victor Nizet, for their support and guidance throughout my PhD candidature. I would also like to thank the members of the Walker lab and the Nizet lab for their friendship, support, guidance and encouragement over the last few years.

I extend my thanks to all contributors and co-authors of the work contained in this thesis: Ramy Aziz, John Buchanan, Gursharan S. Chhatwal, Jason Cole, Katrin Dinkla, Anna Henningham, Rita Kansal, Josh Kirk, Malak Kotb, Jason McArthur, Sarah R Osvath, Morgan Pence, Martina Sanderson-Smith, Amelia Simpson, Anjuli Timmer, Lynne Turnbull and Cynthia B Whitchurch. I would also like to thank the following for their assistance: Arthur Jeng and Kalpana Chalasani for constructing the isogenic mutant 5448 Δ *smez*; Ramy Attia for assisting with real-time PCR; Grant Ellmers and Robert Dinnervill for illustrating Figure 2.5; Anna Cogen for her assistance with a murine model of colonization; William L. Taylor (University of Tennessee, Molecular Resource Center) for his help and guidance in hybridizing and scanning microarrays.

Last but definitely not least, I wish to express my deep gratitude to my family and my wife Terrie for their understanding and encouragement that has helped me maintain dedication throughout the course of my PhD.

TABLE OF CONTENTS

Title.....	i
Declaration.....	ii
Abstract.....	iii
Acknowledgements.....	vi
Table of Contents	vii
List of Figures.....	xiii
List of Tables	xv
Abbreviations	xvi
Publications.....	xviii
Conference Presentations	xix
 1. INTRODUCTION	 1
1.1 Overview	1
1.2 The Genus Streptococcus	2
1.3 Group A Streptococcus	3
1.4 Classification of GAS	4
1.5 Epidemiology of GAS.....	7
1.6 Group A Streptococcal Infection and Disease	9
1.6.1 <i>Superficial group A streptococcal disease</i>	10
1.6.2 <i>Toxin-mediated disease</i>	10
1.6.3 <i>Immune-mediated sequelae</i>	11
1.6.4 <i>Group A streptococcal invasive disease</i>	12
1.7 Virulence Factors	13

1.7.1	<i>M-protein</i>	13
1.7.2	<i>Hyaluronic acid capsule</i>	14
1.7.3	<i>C5a peptidase</i>	14
1.7.4	<i>Extracellular matrix binding proteins and lipoteichoic acid</i>	15
1.7.5	<i>Hyaluronidase</i>	18
1.7.6	<i>Streptokinase</i>	19
1.7.7	<i>Extracellular DNases</i>	19
1.7.8	<i>Streptococcal inhibitor of complement</i>	20
1.7.9	<i>IL-8 protease</i>	21
1.7.10	<i>Streptolysin O and streptolysin S</i>	21
1.7.11	<i>Streptococcal superantigens</i>	22
1.7.12	<i>SpeB</i>	23
1.8	The CovR/S Regulatory System	24
1.9	Project Aims	27

2.	DNASE-MEDIATED RESISTANCE TO NEUTROPHIL KILLING PROVIDES SELECTION PRESSURE FOR A GENETIC AND PHENOTYPIC SWITCH, PROMOTING INVASIVE GROUP A STREPTOCOCCAL INFECTION	28
2.1	Introduction	28
2.2	Materials and Methods	29
2.2.1	<i>Culture of group A streptococci</i>	29
2.2.2	<i>Construction of recombinant group A streptococcal strains</i>	29
2.2.3	<i>DNA sequence analysis of the covR/S operon</i>	32
2.2.4	<i>SpeB activity assays</i>	33

2.2.5	<i>Western blot analysis</i>	33
2.2.6	<i>Plasminogen binding and cell surface plasmin activity</i>	34
2.2.7	<i>Virulence of group A streptococci in a humanised plasminogen transgenic mouse model</i>	36
2.2.8	<i>Tissue chamber implantation and fluid recovery</i>	36
2.2.9	<i>DNase activity assays</i>	37
2.2.10	<i>Live cell imaging for visualization of NETs</i>	37
2.2.11	<i>Neutrophil killing assays</i>	38
2.2.12	<i>Monitoring the in vivo phase-shift of group A streptococcal strains</i>	39
2.2.13	<i>Statistical analyses</i>	39
2.2.14	<i>Ethics approvals</i>	40
2.2.15	<i>Experimental acknowledgements</i>	40
2.3	Results	42
2.3.1	<i>covS mutation results in loss of SpeB expression</i>	42
2.3.2	<i>covS mutation group A streptococci accumulate greater levels of surface plasmin</i>	43
2.3.3	<i>covS mutation confers increased virulence and dissemination to organs</i>	43
2.3.4	<i>covS mutation results in increased DNase activity in vitro and in vivo</i>	45
2.3.5	<i>covS mutation results in increased clearance of NETs and increased resistance to killing by neutrophils</i>	46
2.3.6	<i>sda1 is essential for the in vivo switch to a SpeB-negative phenotype</i>	46
2.4	Discussion	50

3. THE COST OF EVOLUTION TO A HYPERVIRULENT PHENOTYPE BY MIT1 GROUP A STREPTOCOCCUS IS REDUCED CAPACITY TO COLONIZE	53
3.1 Introduction	53
3.2 Materials and Methods	55
3.2.1 <i>Bacterial strains, media and growth conditions</i>	55
3.2.2 <i>Allelic exchange mutagenesis</i>	55
3.2.3 <i>ECM binding assays</i>	56
3.2.4 <i>Epithelial cell adherence assays</i>	56
3.2.5 <i>Hyaluronic acid capsule assay</i>	57
3.2.6 <i>Biofilm quantification assay</i>	57
3.2.7 <i>In vivo adherence assay</i>	58
3.2.8 <i>Growth curves</i>	58
3.2.9 <i>Chain length assays</i>	59
3.2.10 <i>Anti-microbial peptide resistance assays</i>	59
3.2.11 <i>Ethics approval</i>	60
3.2.12 <i>Experimental acknowledgements</i>	60
3.3 Results	61
3.3.1 <i>covS mutant MIT1 group A streptococci have reduced capacity to bind ECM components</i>	61
3.3.2 <i>Ability to adhere to epithelial cells is reduced in covS mutant MIT1 group A streptococci</i>	62
3.3.3 <i>Biofilm formation is reduced in covS mutant MIT1 group A streptococci</i> ...	63
3.3.4 <i>covS mutant MIT1 group A streptococci have reduced capacity to colonise</i>	64

3.4 Discussion	66
 4. A NATURALLY OCCURRING MUTATION IN ROPB SUPPRESSES SPEB EXPRESSION AND REDUCES M1T1 GROUP A STREPTOCOCCAL SYSTEMIC VIRULENCE.....	70
4.1 Introduction	70
4.2 Materials and Methods	72
4.2.1 <i>Bacterial strains, media and growth conditions</i>	72
4.2.2 <i>Sequencing</i>	73
4.2.3 <i>Allelic exchange mutagenesis</i>	73
4.2.4 <i>SpeB activity assays</i>	75
4.2.5 <i>SpeB western blot</i>	75
4.2.6 <i>Haemolytic activity assay</i>	76
4.2.7 <i>DNase activity assays</i>	76
4.2.8 <i>Neutrophil killing assays</i>	77
4.2.9 <i>In vivo SpeB switching studies</i>	77
4.2.10 <i>Tissue cage implantation and in vivo bacterial growth</i>	78
4.2.11 <i>Expression microarrays</i>	78
4.2.12 <i>cDNA preparation and microarray hybridization</i>	79
4.2.13 <i>Analysis of microarray data</i>	79
4.2.14 <i>Murine systemic infection models</i>	80
4.2.15 <i>Experimental acknowledgements</i>	80
4.3 Results	81
4.3.1 <i>Sequence analysis of clinical isolate 5628 reveals intact speB and covR/S but mutation in ropB</i>	81

4.3.2	<i>Repair of the 5628 ropB allele restores SpeB expression and activity</i>	82
4.3.3	<i>ropB mutation does not affect bacterial growth, haemolysis, DNase activity or resistance to neutrophil killing</i>	82
4.3.4	<i>SpeB-positive bacteria revert to a SpeB-negative phenotype on subcutaneous infection</i>	84
4.3.5	<i>SpeB is the principal target of RopB regulation in vivo</i>	85
4.3.6	<i>RopB is required for virulence in systemic infection</i>	86
4.4	Discussion	88
5.	CONCLUSIONS	92
6.	REFERENCES.....	95
7.	APPENDIX	116

LIST OF FIGURES

Figure 1.1	Schematic diagram of the fibrillar coiled-coil streptococcal M-protein	5
Figure 1.2	Hypothetical two-step model of adhesion of group A streptococcus with host tissue	16
Figure 1.3	Proposed model for group A streptococcal systemic disease initiation	26
Figure 2.1	DNA sequence analysis and SpeB expression of GAS strains 5448 and 5448AP	42
Figure 2.2	Molecular and phenotypic analyses of GAS strains 5448 and 5448AP	42
Figure 2.3	Virulence in humanised plasminogen transgenic mice	45
Figure 2.4	DNase activity assays <i>in vitro</i> and <i>in vivo</i>	46
Figure 2.5	Clearance of NETs by group A streptococci and resistance to killing by neutrophils	47
Figure 2.6	The capacity of group A streptococci to phase-shift to a SpeB-negative phenotype	48
Figure 2.7	Model for group A streptococcal invasive disease initiation and progression	52
Figure 3.1	<i>covR/S</i> mutation results in reduced binding to the extracellular matrix	61
Figure 3.2	<i>covR/S</i> mutation results in reduced capacity to adhere to epithelial cells	63
Figure 3.3	<i>covR/S</i> mutation reduces biofilm formation	64

Figure 3.4	<i>covR/S</i> mutation results in reduced colonization capacity	65
Figure 3.5	<i>covR/S</i> mutation doesn not alter growth characteristics.....	65
Figure 4.1	Mutation in <i>ropB</i> results in truncation of the RopB protein and abrogation of <i>SpeB</i> expression.....	83
Figure 4.2	<i>ropB</i> mutation doesn not affect in vitro growth, haemolytic activity, extracellular DNase activty or resistance to neutrophil killing	84
Figure 4.3	Microarray analysis emphasizes the down-regulation of <i>speB</i> operon.....	86
Figure 4.4	RopB- and <i>SpeB</i> -negative bacteria show reduced cirulence in systemic infection models	87

LIST OF TABLES

Table 1.1	Streptococcal adhesins and their host target molecules	16
Table 2.1	Oligonucleotide primers used for construction of recombinant group A streptococcal strains	31
Table 2.2	Oligonucleotide primers used in this study for <i>covR/S</i> PCR and sequence analysis	32
Table 2.3	Acknowledgement of experimental assistance provided for this section	41
Table 2.4	<i>covR/S</i> DNA sequence analysis of selected group A streptococcal M1T1 SpeB-negative derivates	49
Table 3.1	Acknowledgement of experimental assistance provided for this section	60
Table 3.2	Resistance to killing by the human cathelicidin antimicrobial peptide LL-37	66
Table 4.1	Primers used for sequencing the <i>ropB</i> locus (including <i>speB</i>), the <i>covR/S</i> locus, <i>luxS</i> , <i>rofA</i> and <i>ropA</i>	74
Table 4.2	Acknowledgement of experimental assistance provided for this section	81
Table 4.3	<i>covR/S</i> DNA sequence analysis of selected group A streptococcal M1T1 SpeB-negative derivates	85
Table 7.1	Genes differentially regulated greater than 2-fold from microarray analysis of GAS strains 5448 and 5448R-	116

ABBREVIATIONS

°C	degrees Celsius
aa	amino acid
Ab	antibody
ANOVA	analysis of variance
APSGN	acute post-streptococcal glomerulonephritis
ARF	acute rheumatic fever
BLAST	basic local alignment search tool
bp	base pair
CCD	charge-coupled device
cDNA	complementary DNA
CFU	colony forming units
Cm	chloramphenicol
Co	collagen
CovR/S	control of virulence regulator/sensor
DNA	deoxyribonucleic acid
DTT	dithiothreitol
<i>E. coli</i>	<i>Escherichia coli</i>
ECM	extracellular matrix
EDTA	ethylenediaminetetraacetic acid
Erm	erythromycin
FBP	fibronectin binding protein
FCT	fibronectin-binding, collagen-binding, T-antigen
Fn	fibronectin
<i>g</i>	acceleration due to gravity (9.8 ms ⁻²)
GAPDH	glyceraldehyde-3-phosphate dehydrogenase
GAS	group A streptococcus
GEO	Gene Expression Omnibus
h	hours
HRP	horseradish peroxidase
IgA	immunoglobulin A
IgG	immunoglobulin G
kDa	kilodaltons
LA	Luria-Bertani agar
LB	Luria-Bertani broth
LTA	lipoteichoic acid
M	molar
MBC	minimum bactericidal concentration
MF	mitogenic factor
MHC	major histocompatibility complex
MIAME	minimum information about a microarray experiment
MIC	minimum inhibitory concentration
min	minutes
ml	millilitres
mM	millimolar
mm	millimetres
Mrp	M-related protein

NCBI	National Center for Biotechnology Information
NET	neutrophil extracellular trap
ng	nanogram
nm	nanometres
nt	nucleotide
OD	optical density
ORF	open reading frame
PAI	plasminogen activator inhibitor
PAM	plasminogen-binding group A streptococcal M-like protein
PBS	phosphate buffered saline
PCR	polymerase chain reaction
Prp	PAM-related protein
RBC	red blood cell
RGD	arginine-glycine-aspartic acid
RPMI	Roswell Park Memorial Institute
<i>S. pyogenes</i>	<i>Streptococcus pyogenes</i>
SCP	streptococcal C5a peptidase
SD	standard deviation
Sda1	streptodornase 1
SDH	streptococcal surface dehydrogenase
SDS-PAGE	sodium dodecyl sulphate polyacrylamide gel electrophoresis
SEN	streptococcal surface enolase
SIC	streptococcal inhibitor of complement-mediated lysis
Ska	streptokinase
SLO	streptolysin O
SLS	streptolysin S
SmeZ	streptococcal mitogenic exotoxin Z
SOF	serum opacity factor
Spe	streptococcal pyrogenic exotoxin
SpyCEP	<i>Streptococcus pyogenes</i> cell envelope protease
SSA	streptococcal superantigen
STSS	streptococcal toxic shock syndrome
TCA	trichloroacetic acid
TCF	tissue chamber fluid
THA	Todd-Hewitt agar
THB	Todd-Hewitt broth
THY	Todd-Hewitt broth supplemented with 1% (w/v) yeast extract
TNF	tumor necrosis factor
USA	United States of America
V	volts
v/v	volume/volume
w/v	weight/volume
WT	wildtype
μl	microlitres
μm	micrometres
μM	micromolar

PUBLICATIONS

Walker, M. J., **Hollands, A.**, Sanderson-Smith, M. L., Cole, J. N., Kirk, J. K., Henningham, A., McArthur, J. D., Dinkla, K., Aziz, R. K., Kansal, R. G., Simpson, A. J., Buchanan, J. T., Chhatwal, G. S., Kotb, M. and Nizet, V. (2007). DNase Sda1 provides selection pressure for a switch to invasive group A streptococcal infection. *Nature Medicine* **13**(8): 981-5.

Hollands, A., Aziz, R. K, Kansal, R., Kotb, M., Nizet, V., Walker, M. J. (2008). A naturally occurring mutation in *ropB* suppresses SpeB expression and reduces M1T1 group A streptococcal systemic virulence. *PLoS ONE* **3**(12): e4102.

Hollands, A., Pence, M. A., Timmer, A. M., Osvath, S. R, Turnbull, L., Whitchurch, C. B., Walker, M. J., Nizet, V. The cost of evolution to a hypervirulent phenotype by M1T1 group A streptococcus is reduced capacity to colonize. *Manuscript in preparation.*

CONFERENCE PRESENTATIONS

Hollands, A., Aziz, R. K., Kansal, R., Kotb, M., Nizet, V., Walker, M. J. (2008)
Mutation in *ropB* suppresses *speB* expression and reduces group A streptococcal virulence. XVII Lancefield International Symposium on Streptococci and Streptococcal Diseases. June 22-26 Porto Heli, Greece.